Hikal [HIKAL] vs Sequent Scientific [SEQUENT] Detailed Stock Comparison
Hikal
NSE
Loading...
Sequent Scientific
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Hikal wins in 17 metrics, Sequent Scientific wins in 2 metrics, with 0 ties. Hikal appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Hikal | Sequent Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 39.25 | 195.40 | Hikal |
| Price-to-Book Ratio | 2.82 | 5.96 | Hikal |
| Debt-to-Equity Ratio | 60.58 | 62.47 | Hikal |
| PEG Ratio | 22.45 | 33.28 | Hikal |
| EV/EBITDA | 13.07 | 29.60 | Hikal |
| Profit Margin (TTM) | 4.88% | 1.41% | Hikal |
| Operating Margin (TTM) | 15.51% | 9.41% | Hikal |
| EBITDA Margin (TTM) | 15.51% | 9.41% | Hikal |
| Return on Equity | 7.41% | 4.35% | Hikal |
| Return on Assets (TTM) | 4.96% | 4.01% | Hikal |
| Free Cash Flow (TTM) | $1.43B | $442.70M | Hikal |
| Dividend Yield | 0.33% | N/A | N/A |
| 1-Year Return | -9.26% | 22.29% | Sequent Scientific |
| Price-to-Sales Ratio (TTM) | 2.01 | 2.71 | Hikal |
| Enterprise Value | $43.58B | $46.83B | Sequent Scientific |
| EV/Revenue Ratio | 2.34 | 3.02 | Hikal |
| Gross Profit Margin (TTM) | 57.78% | 50.28% | Hikal |
| Revenue per Share (TTM) | $151 | $62 | Hikal |
| Earnings per Share (Diluted) | $7.35 | $0.86 | Hikal |
| Beta (Stock Volatility) | 0.47 | 0.91 | Hikal |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Hikal vs Sequent Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Hikal | -0.73% | -8.40% | -15.52% | -23.70% | -18.21% | -27.86% |
| Sequent Scientific | -3.97% | -0.34% | -9.41% | 8.30% | 7.32% | -9.00% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Hikal | -9.26% | 7.51% | 115.66% | 268.92% | 461.33% | 254.69% |
| Sequent Scientific | 22.29% | 57.12% | 26.68% | 13.98% | 13.98% | 13.98% |
Performance & Financial Health Analysis: Hikal vs Sequent Scientific
| Metric | HIKAL | SEQUENT |
|---|---|---|
| Market Information | ||
| Market Cap | ₹37.35B | ₹42.04B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 321,502 | 673,998 |
| 90 Day Avg. Volume | 287,757 | 526,426 |
| Last Close | ₹290.60 | ₹168.04 |
| 52 Week Range | ₹281.00 - ₹464.75 | ₹117.35 - ₹240.70 |
| % from 52W High | -37.47% | -30.19% |
| All-Time High | ₹742.00 (Aug 16, 2021) | ₹336.50 (Jun 28, 2021) |
| % from All-Time High | -60.84% | -50.06% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.11% |
| Quarterly Earnings Growth | 0.48% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.05% | 0.01% |
| Operating Margin (TTM) | 0.16% | 0.09% |
| Return on Equity (TTM) | 0.07% | 0.04% |
| Debt to Equity (MRQ) | 60.58 | 62.47 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹102.34 | ₹28.19 |
| Cash per Share (MRQ) | ₹1.46 | ₹2.52 |
| Operating Cash Flow (TTM) | ₹2.80B | ₹833.62M |
| Levered Free Cash Flow (TTM) | ₹808.52M | ₹453.76M |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.33% | N/A |
| Last 12-Month Dividend | ₹1.20 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Hikal vs Sequent Scientific
| Metric | HIKAL | SEQUENT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 39.25 | 195.40 |
| Forward P/E | 22.45 | 33.28 |
| PEG Ratio | 22.45 | 33.28 |
| Price to Sales (TTM) | 2.01 | 2.71 |
| Price to Book (MRQ) | 2.82 | 5.96 |
| Market Capitalization | ||
| Market Capitalization | ₹37.35B | ₹42.04B |
| Enterprise Value | ₹43.58B | ₹46.83B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.34 | 3.02 |
| Enterprise to EBITDA | 13.07 | 29.60 |
| Risk & Other Metrics | ||
| Beta | 0.47 | 0.91 |
| Book Value per Share (MRQ) | ₹102.34 | ₹28.19 |
Financial Statements Comparison: Hikal vs Sequent Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HIKAL | SEQUENT |
|---|---|---|
| Revenue/Sales | ₹5.50B | ₹4.02B |
| Cost of Goods Sold | ₹2.32B | ₹2.00B |
| Gross Profit | ₹3.18B | ₹2.02B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹857.00M | ₹294.80M |
| EBITDA | ₹1.24B | ₹442.10M |
| Pre-Tax Income | ₹683.00M | ₹163.10M |
| Income Tax | ₹181.00M | ₹59.30M |
| Net Income (Profit) | ₹502.00M | ₹103.80M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HIKAL | SEQUENT |
|---|---|---|
| Cash & Equivalents | ₹130.00M | ₹626.60M |
| Total Current Assets | ₹9.95B | ₹8.74B |
| Total Current Liabilities | ₹7.90B | ₹5.05B |
| Long-Term Debt | ₹3.70B | ₹3.00B |
| Total Shareholders Equity | ₹12.62B | ₹7.70B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹13.57B | ₹2.84B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HIKAL | SEQUENT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | HIKAL | SEQUENT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 321,502 | 673,998 |
| Average Daily Volume (90 Day) | 287,757 | 526,426 |
| Shares Outstanding | 123.30M | 249.89M |
| Float Shares | 38.08M | 117.77M |
| % Held by Insiders | 0.69% | 0.53% |
| % Held by Institutions | 0.09% | 0.13% |
Dividend Analysis & Yield Comparison: Hikal vs Sequent Scientific
| Metric | HIKAL | SEQUENT |
|---|---|---|
| Last 12-Month Dividend | ₹1.20 | ₹0.00 |
| Last 12-Month Dividend Yield | 0.33% | N/A |
| 3-Year Avg Annual Dividend | ₹1.13 | ₹0.00 |
| 3-Year Avg Dividend Yield | 0.18% | N/A |
| 3-Year Total Dividends | ₹3.40 | ₹0.00 |
| Ex-Dividend Date | Feb 07, 2025 | N/A |